Tempus AI announced the expansion of its TIME Network to support Phase I clinical trials, aiming to accelerate activation and enrollment. Since its inception in 2019, TIME has facilitated rapid patient identification and site activation for clinical trials across the U.S.
To further enhance its support for early-phase trials, Tempus has formed the TIME Precision Network, a group of investigators focused on quickly activating and enrolling patients across over 40 phase I-capable research centers. This initiative adds a critical capability to the TIME Network.
The TIME Network is powered to efficiently enroll patients within its participating data-integrated site base, identifying patients and activating sites within days or weeks. For example, the Taylor Cancer Research Center activated a site in approximately two weeks for the Nimbus 9216-101 study and enrolled its first patient within one month.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.